MicroRNA Signatures in Lung Adenocarcinoma Metastases: Exploring the Oncogenic Targets of Tumor-Suppressive

Yuya Tomioka1, Naohiko Seki2, Keiko Mizuno1

  • 1Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.

Cancers
|July 29, 2025
PubMed

Insights

MicroRNAs miR-195-5p and miR-195-3p suppress lung adenocarcinoma brain metastasis by inhibiting cell proliferation and invasion. Targeting their downstream genes like ANLN and MAD2L1 offers new therapeutic strategies for lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung adenocarcinoma (LUAD) requires novel treatments for metastatic disease.
  • Metastatic lesions present significant challenges in improving patient prognosis.
  • Targeting molecular mechanisms of metastasis is crucial for LUAD treatment.

Purpose of the Study:

  • To identify microRNAs (miRNAs) involved in LUAD brain metastasis.
  • To elucidate the tumor-suppressive functions of identified miRNAs.
  • To discover oncogenic genes regulated by these miRNAs in LUAD.

Main Methods:

  • RNA sequencing to generate miRNA expression signatures of brain metastases.
  • Ectopic expression assays to validate miRNA function.
  • Bioinformatic analysis to identify miRNA target genes.

Main Results:

  • Identified downregulated miRNAs in brain metastases, including both strands of pre-miR-195 (miR-195-5p and miR-195-3p).
  • Demonstrated that both miR-195-5p and miR-195-3p attenuate LUAD cell proliferation, migration, and invasion.
  • Identified 12 cell cycle/division-related target genes, including ANLN and MAD2L1, regulated by these miRNAs.

Conclusions:

  • Both strands of pre-miR-195 exhibit tumor-suppressive functions in LUAD.
  • The identified miRNA signature from brain metastasis is a significant finding.
  • Targeting ANLN and MAD2L1 may offer therapeutic avenues for LUAD brain metastasis.